drugset / Trial / NCT07370155
Study Evaluating Safety & Tolerability of Migaldendranib in Healthy Volunteers
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, open-label, multiple-dose study to evaluate the safety, tolerability, and PK of MGB after weekly subQ MGB administration in up to 36 healthy volunteers at 1 site in Australia.
Timeline
- Start
- 2026-01-29
- Primary completion
- 2026-08-13
- Completion
- 2026-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Migaldendranib | Small molecule | 200 mg | Subcutaneous |
| Subject | Migaldendranib | Small molecule | 400 mg | Subcutaneous |
| Subject | Migaldendranib | Small molecule | 600 mg | Subcutaneous |
Indications
No indication recorded.